953048-71-0

Basic information

• Product Name: 5-Amino-1,3,3-trimethyl-2-oxindole
• Synonyms: 5-Amino-1,3,3-trimethyl-2-oxindole;5-Amino-1,3,3-trimethyl-2...;5-AMino-1,3,3-triMethyl-2-oxoindoline;5-Amino-1,3,3-trimethyl-indolin-2-one;5-amino-1,3,3-trimethyl-2,3-dihydro-1H-indol-2-one
• CAS NO: 953048-71-0
• Molecular Formula: C₁₁H₁₄N₂O
• Molecular Weight: 190.24166
• Mol File: 953048-71-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-Amino-1,3,3-trimethyl-2-oxindole(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Amino-1,3,3-trimethyl-2-oxindole(953048-71-0)
• EPA Substance Registry System: 5-Amino-1,3,3-trimethyl-2-oxindole(953048-71-0)

Safety Data

• Hazardous Substances Data: 953048-71-0(Hazardous Substances Data)

Usage

Uses

Used in Textile Industry:
5-Amino-1,3,3-trimethyl-2-oxindole is used as a dye for its bright yellow color, providing a vibrant hue to fabrics and textiles.
Used in Paper Industry:
In the paper industry, 5-Amino-1,3,3-trimethyl-2-oxindole serves as a dye, enhancing the visual appeal of paper products with its distinctive yellow shade.
Used in Medicinal Chemistry:
5-Amino-1,3,3-trimethyl-2-oxindole is used as a subject of interest in medicinal chemistry due to its potential biological activity, including antiviral and antibacterial properties, making it a promising candidate for drug development.
Used in Drug Development:
In drug development, 5-Amino-1,3,3-trimethyl-2-oxindole is utilized for its potential therapeutic applications, as its antiviral and antibacterial properties are being explored for the creation of new medications to combat various diseases.

Upstream product

• 120791-55-1 1,3-dihydro-1,3,3-trimethyl-5-nitro-2H-indole-2-one 
• 20200-86-6 1,3,3-trimethyl-1,3-dihydro-2H-indol-2-one 

Relevant articles and documents

SUBSTITUTED URACILS AS CHYMASE INHIBITORS

Substituted uracil derivatives of formula (I), processes for their preparation, their use alone or in combinations for the treatment and/or prophylaxis of diseases, and their use for preparing medicaments for the treatment and/or prophylaxis of diseases.

BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF

The present application relates to novel bicyclically substituted uracil derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases.

Sequential one-pot access to molecular diversity through aniline aqueous borylation

On the basis of our recently reported aniline aqueous borylation, molecular diversity was achieved in a one-pot process by combining other reactions such as esterification, Suzuki-Miyaura coupling, hydrogenolysis, or Petasis borono-Mannich.

Nonsteroidal Cardiotonics. 2. The Inotropic Activity of Linear, Tricyclic 5-6-5 Fused Heterocycles

We previously reported the structure-activity relationships (SAR) of adibendan (1), a potent and long-acting cardiotonic.This paper describes the synthesis of a novel series of linear, tricyclic fused heterocycles of the 5-6-5 type.The compounds were evaluated for positive inotropic activity in anesthetized rats, cats, and dogs.Changes in left ventricular dP/dt were measured as an index of cardiac contractility.The increase in contractility was not mediated via stimulation of β-adrenergic receptors.The data revealed the intrinsic positive inotropic activity of the parent compound of this series, 5,7-dihydro-7,7-dimethylpyrrolobenzimidazol-6(1H)-one (2).The structural features that impart optimal inotropic activity are presented and compared with those of the 4,5-dihydro-3(2H)-pyridazinone series.The most potent compounds were evaluated orally in conscious dogs with implanted Konigsberg pressure transducers to measure ventricular pressures, and their effect on left ventricular dP/dt was compared with that of 1, pimobendan, and indolidan.After administration of 1 mg/kg, 1, 3, 7, 19, 22, 24, 31, 54, pimobendan, and indolidan were equipotent, but only with 1, 31, pimobendan, and indolidan, durations of action exceeded 6 h.